RYTM

Rhythm Pharmaceuticals, Inc.

A biopharmaceutical company that makes medicines for rare genetic diseases of severe obesity, marked by insatiable hunger and excess weight gain. Its marketed drug, IMCIVREE (setmelanotide), is a precision medicine that restores a signaling pathway in the brain controlling hunger and fullness for patients with conditions such as Bardet-Biedl syndrome and POMC deficiency. Founded in 2008 in Boston, the company's name echoes the body's internal rhythm of hunger and metabolism its medicines aim to reset.

CUSIP: 76243J105HealthcareUS1 holder

Ownership Activity Financials Filings

RYTM

RYTM

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Regulation FD Disclosure

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Regulation FD Disclosure

Regulation FD Disclosure

Regulation FD Disclosure